Tempus AI, based in Chicago, Illinois, went public on June 14, 2024, providing next-generation diagnostics through genomics and AI applications aimed at personalizing medicine. Its primary product, Next, uses machine learning to enhance oncology and cardiology care.
Theodore Leonsis sold 205,847 shares of TEM on 11 June at $68.27 per share, worth a total of $14.1M. They now own 21,731 TEM shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.